[Lung surfactant changes in acute destructive pancreatitis]

Area of Science:

• Biomedical Research
• Pulmonary Medicine
• Gastroenterology

Background:

• Severe acute pancreatitis (SAP) poses significant mortality risks and frequently leads to respiratory complications.
• Pulmonary surfactant (PS) alterations are implicated in SAP-induced lung injury.
• Structural phospholipids in PS, such as lecithin and sphyngomyelin, are crucial for lung function.

Purpose of the Study:

• To investigate the impact of SAP on pulmonary surfactant (PS) phospholipids (lecithin and sphyngomyelin) in an experimental canine model.
• To evaluate the efficacy of Sandostatin treatment in mitigating SAP-induced changes in PS phospholipids.
• To assess alterations in bronchoalveolar lavage (BAL) fluid composition during SAP.

Main Methods:

• Experimental induction of severe acute pancreatitis (SAP) in 26 dogs.
• Administration of Sandostatin treatment to one group of dogs, with another group left untreated.
• Measurement of pulmonary surfactant (PS) phospholipid fractions (lecithin and sphyngomyelin) in bronchoalveolar lavage (BAL) fluid at multiple time points (1, 3, 6, 12, and 24 hours).
• Comparison of PS phospholipid levels between treated and untreated groups, and against pre-pancreatitis baseline.

Main Results:

• A significant reduction in lecithin and sphyngomyelin levels was observed in the BAL fluid of dogs with SAP.
• Sandostatin treatment demonstrated a statistically significant attenuation of this reduction compared to untreated dogs.
• The study confirmed SAP-induced alterations in key surfactant phospholipid values.

Conclusions:

• Severe acute pancreatitis significantly depletes pulmonary surfactant (PS) phospholipids, specifically lecithin and sphyngomyelin.
• Sandostatin treatment may offer a protective effect against SAP-induced surfactant dysfunction.
• These findings highlight the role of surfactant changes in SAP pathophysiology and suggest therapeutic potential for Sandostatin.